Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity

BACKGROUND: Immune checkpoint blockade (ICB) has revolutionized cancer immunotherapy. However, most patients with cancer fail to respond clinically. One potential reason is the accumulation of immunosuppressive transforming growth factor β (TGFβ) in the tumor microenvironment (TME). TGFβ drives canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Anqi, Chang, Yuzhou, Song, No-Joon, Wu, Xingjun, Chung, Dongjun, Riesenberg, Brian P, Velegraki, Maria, Giuliani, Giuseppe D, Das, Komal, Okimoto, Tamio, Kwon, Hyunwoo, Chakravarthy, Karthik B, Bolyard, Chelsea, Wang, Yi, He, Kai, Gatti-Mays, Margaret, Das, Jayajit, Yang, Yiping, Gewirth, Daniel T, Ma, Qin, Carbone, David, Li, Zihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472209/
https://www.ncbi.nlm.nih.gov/pubmed/36096533
http://dx.doi.org/10.1136/jitc-2022-005433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472209/
https://www.ncbi.nlm.nih.gov/pubmed/36096533
http://dx.doi.org/10.1136/jitc-2022-005433

Ejemplares similares